Multiple double-blind placebo-controlled human clinical trials (Ried et al. Front Nutr 2018 & Budoff et al. JACC 2020).
Aged Garlic Extract (1,200mg Kyolic)
Standardized 1,200mg aged garlic extract supplying water-soluble S-Allyl Cysteine to reverse arterial stiffness and halt soft plaque progression.
Multiple double-blind placebo-controlled human clinical trials (Ried et al. Front Nutr 2018 & Budoff et al. JACC 2020).
Long-term multi-cohort replication and optimal individualization remain active areas of study.
Aged Garlic Extract Lowers Blood Pressure, Improves Arterial Stiffness and Gut Microbiota in Hypertensive Patients
“Central Systolic Blood Pressure: -8.7 mmHg”
Aged Garlic Extract Lowers Blood Pressure, Improves Arterial Stiffness and Gut Microbiota in Hypertensive Patients
“Aged Garlic Extract standardized for S-allylcysteine significantly drops central aortic pressure, improves arterial elasticity, and retards soft coronary plaque progression.”
Scientific Dual-Coverage Profile
Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.
Heart & Cardiovascular
Foundational Target (65-100)S-allylcysteine (SAC) stimulates hydrogen sulfide (H2S) and nitric oxide release, relaxing vascular smooth muscle and inhibiting soft coronary plaque formation by 80%.
Brain Longevity & Cognition
Synergistic Target (30-64)Central blood pressure reduction and plaque stabilization shield cerebral capillaries from hypertensive micro-bleeds.
Metabolic & Glycemic Health
Synergistic Target (30-64)Supports beneficial commensal gut bacteria, reducing systemic endotoxin-driven metabolic friction.
Cancer Defense & Autophagy
Synergistic Target (30-64)Organosulfur compounds stimulate hepatic Phase II xenobiotic conjugation and electrophile excretion.
Endocrine Vitality & Anabolic Tone
Neutral PathwayNo direct modulation of Leydig steroidogenesis.
Systemic Inflammation Suppression
Foundational Target (65-100)Aged organosulfur constituents scavenge peroxynitrite and inhibit inflammatory cytokine gene expression in arterial walls.
Bone Density & Connective Matrix
Neutral PathwayNo direct osteoblast Piezo1 mechanotransduction or bone mineral deposition.
Cellular Longevity & Epigenetics
Foundational Target (65-100)Enhances intracellular antioxidant defenses via Nrf2 pathway activation, protecting endothelial cell membranes from oxidative stress.
Functional Outcomes & Performance Impact
Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.
Coronary Vascular Elasticity
Clinical Endpoint: Reduces central SBP by -8.7 mmHg, decreases arterial pulse-wave stiffness, and slows soft plaque progression by 80%.
Score Breakdown: 88 / 100
Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.
Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).
Adverse event frequency, toxicology window, long-term organ tolerability.
Multi-system pleiotropy across the 8 canonical longevity vectors.
Affordability, time burden, friction to sustained daily/weekly compliance.
Practicality, Cost & Adherence Index
Aged Garlic Extract (1,200mg Kyolic) Multi-Trial Scientific Evidence
Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.
Aged Garlic Extract (1,200mg Kyolic) Evidence Timeline
Initial Mechanistic Validation
Early molecular characterization demonstrates direct modulation of cellular stress pathways.
Controlled Human Pilot Trial
Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.
Aged Garlic Extract (1,200mg Kyolic) Safety Matrix
Absolute Contraindications (Do Not Use)
- •Upcoming major surgery within 7 days (mild platelet anti-aggregation)
Pharmacological & Supplement Interactions
No high-risk pharmacokinetic interactions documented.
Proven Adverse Effects vs. Theoretical Risks
- Transient and mild when used at therapeutic doses.
Under-Researched Populations (Evidence Gaps)
Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:
- Premenopausal women
- Pediatric cohorts
Biological Relationship Graph
Combines safely with baseline longevity routines.
No direct clinical antagonisms detected.